Imatinib-refractory gastrointestinal stromal tumors: the clinical problem and therapeutic strategies.

Current Oncology Reports
Margaret von Mehren

Abstract

Treatment of gastrointestinal stromal tumor (GIST) is a paradigm for targeted therapy. These mesenchymal tumors are refractory to standard chemotherapy and radiation therapy. Targeted therapy has successfully exploited the oncologic drivers of GIST--the tyrosine kinases, KIT, and the platelet-derived growth factor receptor. Therapy with imatinib has dramatically altered the natural history of patients with advanced GIST. However, patients are developing resistance to imatinib and thus presenting with a major clinical challenge. Alternative approaches to imatinib-refractory disease are needed. Newer approaches using biologic data regarding the mechanisms of resistance are being tested alone or in combination with imatinib and are the focus of this review. Effective novel agents for imatinib-refractory GIST used as single agents or in combination with imatinib will likely become future regimens to be tested in first-line metastatic disease and in the adjuvant setting.

References

Sep 1, 1983·The American Journal of Surgical Pathology·M T Mazur, H B Clark
Feb 1, 1995·The American Journal of Surgical Pathology·M Miettinen Maarit-Sarlomo-Rikala
Oct 18, 2000·Annals of Surgical Oncology·I PidhoreckyJ F Gibbs
Aug 21, 2001·Surgery Today·Y TakahashiS Yokoyama
Oct 31, 2001·The American Journal of Surgical Pathology·M Miettinen, L H Sobin
Nov 14, 2001·Lancet·A T van OosteromUNKNOWN European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
Jul 3, 2002·Human Pathology·Ronald P DematteoGeorge Demetri
Aug 16, 2002·The New England Journal of Medicine·George D DemetriHeikki Joensuu
Jan 17, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Allan T van OosteromUNKNOWN European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
Sep 6, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J VerweijO S Nielsen
Jul 17, 2004·Science·Neil P ShahCharles L Sawyers
Jan 19, 2005·The American Journal of Gastroenterology·Thomas TranHashem B El-Serag
Feb 16, 2005·Cancer Cell·Ellen WeisbergJames D Griffin
May 19, 2005·International Journal of Cancer. Journal International Du Cancer·Geir TryggvasonJón G Jónasson
Oct 26, 2005·Current Treatment Options in Oncology·Chi Tarn, Andrew K Godwin

❮ Previous
Next ❯

Citations

Oct 26, 2005·Current Treatment Options in Oncology·Chi Tarn, Andrew K Godwin
Aug 25, 2012·The British Journal of Radiology·C G CroninS McDermott
Feb 3, 2009·The Surgical Clinics of North America·T Peter Kingham, Ronald P DeMatteo
Aug 1, 2015·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Heikki JoensuuMichael Montemurro
Apr 29, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Chun-Yan DuYing-Qiang Shi
Sep 29, 2011·Clinical Journal of Oncology Nursing·Tamara Barnes, Denise Reinke
Nov 7, 2008·Nuclear Medicine Communications·Sandip BasuManoj Vyawahare
Jan 18, 2018·Chinese Medical Journal·Emine Elif Ozkan
Nov 15, 2006·Clinical Colorectal Cancer·Chi Tarn, Andrew K Godwin

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.